Denali: Positive Results in Early Stage Studies of Parkinson’s Treatment

 

• Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease
  

• BIIB122/DNL151 demonstrated a safety profile supporting continued development in patients with Parkinson’s disease

• Data support once daily oral dosing with BIIB122/DNL151

• Denali and Biogen plan to advance BIIB122/DNL151 into late-stage development in patients with Parkinson’s disease by year-end 2021

https://finance.yahoo.com/news/denali-therapeutics-presents-positive-results-130000554.html